

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1624

Carlos GARCIA-ECHEVERRIA et al.

Examiner: RAO, Deepak R.

APPLICATION NO: 10/568,367

FILED: 18 August 2006

FOR: 2,4-Pyrimidinediamines Useful in the Treatment of Neoplastic Diseases, Inflammatory and Immune System Disorders

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

**SUBMISSION OF SEQUENCE LISTING
INCLUDING STATEMENT OF VERIFICATION**

Sir:


Applicants hereby provide a Computer Readable Form (CRF) of the Sequence Listing as well as the Paper Copy thereof. The undersigned states that the Paper Copy and the Computer Readable Form (CRF), submitted in accordance with 37 CFR §1.821(c) and (e), respectively, are the same, and include no new matter.

Respectfully submitted,

Novartis Institutes for Biomedical Research, Inc.
220 Massachusetts Avenue
Cambridge, MA 02139

(617) 871-7347

Date: 30 July 2009


Mark E. Baron
Attorney for Applicant
Reg. No. 46,150